JP2024524974A5 - - Google Patents
Info
- Publication number
- JP2024524974A5 JP2024524974A5 JP2023578922A JP2023578922A JP2024524974A5 JP 2024524974 A5 JP2024524974 A5 JP 2024524974A5 JP 2023578922 A JP2023578922 A JP 2023578922A JP 2023578922 A JP2023578922 A JP 2023578922A JP 2024524974 A5 JP2024524974 A5 JP 2024524974A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotides
- approximately
- composition according
- vector
- mrna precursor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163212981P | 2021-06-21 | 2021-06-21 | |
| US63/212,981 | 2021-06-21 | ||
| PCT/US2022/034344 WO2022271699A2 (en) | 2021-06-21 | 2022-06-21 | Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024524974A JP2024524974A (ja) | 2024-07-09 |
| JP2024524974A5 true JP2024524974A5 (enExample) | 2025-07-01 |
Family
ID=84544915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023578922A Pending JP2024524974A (ja) | 2021-06-21 | 2022-06-21 | ナンセンス変異依存ｒｎａ分解機構に基づく病態及び疾患の処置のためのアンチセンスオリゴマー |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240254488A1 (enExample) |
| EP (1) | EP4359538A4 (enExample) |
| JP (1) | JP2024524974A (enExample) |
| CN (1) | CN117980479A (enExample) |
| WO (1) | WO2022271699A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12338437B2 (en) | 2020-05-11 | 2025-06-24 | Stoke Therapeutics, Inc. | OPA1 antisense oligomers for treatment of conditions and diseases |
| TW202504646A (zh) * | 2023-06-16 | 2025-02-01 | 北京大學 | 利用環狀ｒｎａ抑制無義介導的降解的系統和方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1280903A2 (en) * | 2000-05-11 | 2003-02-05 | Maria Rozakis-Adcock | Ph domain-interacting protein |
| US20130288967A1 (en) * | 2012-04-25 | 2013-10-31 | Euclid Diagnostics Llc | Materials and methods for cancer diagnosis by evaluation of the methylation status of cpg islands on chromosomes 6 and 8 |
| US20150376612A1 (en) * | 2014-06-10 | 2015-12-31 | The General Hospital Corporation | CCCTC-Binding Factor (CTCF) RNA Interactome |
| LT3700570T (lt) * | 2017-10-23 | 2025-04-10 | Stoke Therapeutics, Inc. | Priešprasmiai oligomerai, skirti būklių ir ligų, pagrįstų nonsens kodono nulemta mrnr degradacija, gydymui |
| KR20220104677A (ko) * | 2019-08-19 | 2022-07-26 | 스톡 테라퓨틱스, 인크. | 스플라이싱 및 단백질 발현을 조절하기 위한 조성물 및 방법 |
-
2022
- 2022-06-21 CN CN202280057124.6A patent/CN117980479A/zh active Pending
- 2022-06-21 JP JP2023578922A patent/JP2024524974A/ja active Pending
- 2022-06-21 WO PCT/US2022/034344 patent/WO2022271699A2/en not_active Ceased
- 2022-06-21 EP EP22829154.8A patent/EP4359538A4/en active Pending
-
2023
- 2023-12-19 US US18/545,753 patent/US20240254488A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024056778A5 (enExample) | ||
| CN107406852B (zh) | 用于莱伯氏先天性黑蒙的寡核苷酸疗法 | |
| GB2584204A (en) | Antisense oligomers for treatment of non-sense mediated RNA decay based conditions and diseases | |
| JP2021500041A5 (enExample) | ||
| JP2012147790A (ja) | エキソンスキッピングを誘発する為の手段及び方法 | |
| JP2006505251A (ja) | 血管形成のｓｉＲＮＡ阻害のための組成物及び方法 | |
| US11104900B2 (en) | Antisense oligonucleotides to treat dystrophic epidermolysis bullosa | |
| CN107567498B (zh) | 用于大疱性表皮松解症治疗的与col7a1外显子73配对的寡核苷酸 | |
| JP7756166B2 (ja) | Ｒｎａ治療薬及びその使用方法 | |
| JP7048574B2 (ja) | アンチセンスオリゴヌクレオチドおよび糖原病Ｉａ型予防または治療用組成物 | |
| JP2023525799A5 (enExample) | ||
| AU2019344006A1 (en) | Compositions and methods to restore paternal UBE3A gene expression in human Angelman Syndrome | |
| JP2025020293A (ja) | アンチセンスオリゴヌクレオチドは、ａｂｃａ４の異常スプライシングをレスキューする | |
| JP2023506842A5 (enExample) | ||
| US20260139273A1 (en) | Synergistic Nucleic Acid Based Therapeutics and Methods of Use for Treating Genetic Disorders | |
| KR101783444B1 (ko) | miR-33-5p 를 이용한 뇌신경세포 보호 물질 스크리닝 방법 | |
| JP2022532998A5 (enExample) | ||
| WO2017186815A1 (en) | Antisense oligonucleotides for enhanced expression of frataxin | |
| TW202504620A (zh) | 用於治療ｃａｇ重複疾病之組成物和方法 | |
| JP2026502888A (ja) | エピジェネティック調節因子の新規阻害剤 | |
| JP2017506638A (ja) | 肝傷害を治療するための組成物及び方法 | |
| CN118147133A (zh) | 一种调控bax表达的反义寡核苷酸及其应用 | |
| JP2024507717A5 (enExample) | ||
| US20200048632A1 (en) | Antisense Oligonucleotides for Treatment of Spinal Muscular Atrophy | |
| JP2021513851A5 (enExample) |